Geron (GERN) Common Equity (2010 - 2026)
Geron's (GERN) quarterly Common Equity came in at $218.6 million in Q2 2026, down 15.77% year-over-year from $259.5 million in Q2 2025, and down 4.58% quarter-over-quarter from $229.1 million in Q1 2026.
Analysis
Geron (GERN) Common Equity (2010 - 2026) Analysis & Trends
Geron has disclosed Common Equity across 17 years of filings, most recently posting $218.6 million for Q2 2026.
- In Q2 2026, Common Equity fell 15.77% year-over-year to $218.6 million; the TTM figure through Jun 2026 stood at $218.6 million (down 15.77% YoY), while the FY2025 annual figure was $225.9 million, down 19.42% from the prior year.
- Common Equity came in at $218.6 million for Q2 2026 at Geron, down from $229.1 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $344.9 million in Q1 2024 to a low of $80.0 million in Q4 2022.
- Average Common Equity over 5 years is $236.9 million, with a median of $254.1 million recorded in 2025.
- Year-over-year, Common Equity tumbled 51.54% in 2022 and surged 234.46% in 2023.
- Over 5 years, Common Equity stood at $80.0 million in 2022, then jumped by 209.94% to $247.9 million in 2023, then grew by 13.06% to $280.3 million in 2024, then dropped by 19.42% to $225.9 million in 2025, then slipped by 3.21% to $218.6 million in 2026.
- Per Business Quant data, the three most recent Common Equity figures were $218.6 million in Q2 2026, $229.1 million in Q1 2026, and $225.9 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 11.69 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 11.83 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 20.25 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 31.71 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 8.42 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 6.76 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 18.85 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 4.92 Bn |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | 218.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 218.61 Mn |
| Mar 31, 2026 | 229.11 Mn |
| Dec 31, 2025 | 225.87 Mn |
| Sep 30, 2025 | 248.71 Mn |
| Jun 30, 2025 | 259.53 Mn |
| Mar 31, 2025 | 268.24 Mn |
| Dec 31, 2024 | 280.32 Mn |
| Sep 30, 2024 | 292.28 Mn |
| Jun 30, 2024 | 306.70 Mn |
| Mar 31, 2024 | 344.87 Mn |
| Dec 31, 2023 | 247.95 Mn |
| Sep 30, 2023 | 290.61 Mn |
| Jun 30, 2023 | 298.43 Mn |
| Mar 31, 2023 | 326.06 Mn |
| Dec 31, 2022 | 80.00 Mn |
| Sep 30, 2022 | 108.17 Mn |
| Jun 30, 2022 | 142.05 Mn |
| Mar 31, 2022 | 97.49 Mn |
| Dec 31, 2021 | 126.42 Mn |
| Sep 30, 2021 | 151.55 Mn |